SELENBP1 and pancreatic neoplasm: Pancreatic cancer: SELENBP1 is downregulated in pancreatic ductal adenocarcinoma (PDAC) patients with skin rash (SR) treated with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (Caba et al., 2016).